Loading…

Pharmacokinetic and pharmacodynamic properties of insulin aspart and human insulin

The preferred approach to determine the pharmacokinetic (PK) and pharmacodynamic (PD) properties of insulin analogues is the euglycemic glucose clamp. Currently non-compartmental data analytical approaches are used to analyze data. The purpose of the present study is to propose a novel compartmental...

Full description

Saved in:
Bibliographic Details
Published in:Journal of pharmacokinetics and pharmacodynamics 2003-06, Vol.30 (3), p.221-235
Main Authors: ØSTERBERG, Ole, ERICHSEN, Lars, INGWERSEN, Steen H, PLUM, Anne, POULSEN, Henrik E, VICINI, Paolo
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c462t-a4ca9602b81fd0b28753a029f1150682ac8f884f8116e09ba8d6d48033ac67ee3
cites
container_end_page 235
container_issue 3
container_start_page 221
container_title Journal of pharmacokinetics and pharmacodynamics
container_volume 30
creator ØSTERBERG, Ole
ERICHSEN, Lars
INGWERSEN, Steen H
PLUM, Anne
POULSEN, Henrik E
VICINI, Paolo
description The preferred approach to determine the pharmacokinetic (PK) and pharmacodynamic (PD) properties of insulin analogues is the euglycemic glucose clamp. Currently non-compartmental data analytical approaches are used to analyze data. The purpose of the present study is to propose a novel compartmental-model for analysis of data from glucose clamp studies. Data used in this trial only involved 18 of the 20 originally treated subjects. Data was obtained from a crossover trial where 18 healthy subjects each received a single subcutaneous (s.c.) dose of 1.2 nmol/kg (body weight) insulin aspart (IAsp) or 1.2 nmol/kg human insulin (HI) during a euglycemic glucose clamp after overnight fast. Serum insulin and glucose concentrations were measured and the glucose infusion rate (GIR) was adjusted after dosing, to maintain blood glucose near basal levels. Individual model parameters were estimated for IAsp, HI, and the corresponding glucose and GIR data. We found statistically significant differences between most of the HI and IAsp pharmacokinetic parameters, including the sigmoidicity of the time course of absorption (1.5 for HI vs. 2.1 for IAsp (unit less), P = 0.0005, Wilcoxon Signed-rank test), elimination rate constant (0.010 min-1 for HI vs. 0.016 min-1 for IAsp (P = 0.002)). The PD model parameters were mostly not different, except for the rate of insulin action (0.012 min-1 for HI vs. 0.017 min-1 for IAsp (P = 0.03)). The model may provide a framework to account for different PK properties when estimating the PD properties of insulin and insulin analogues in glucose clamp experiments.
doi_str_mv 10.1023/a:1025594110558
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71293714</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71293714</sourcerecordid><originalsourceid>FETCH-LOGICAL-c462t-a4ca9602b81fd0b28753a029f1150682ac8f884f8116e09ba8d6d48033ac67ee3</originalsourceid><addsrcrecordid>eNpdkEtLxTAQhYMovtfupAi6q2byrruL-AJBEQV3ZW6aYrVNa9Iu_PdGrYguhhlmvnMYDiF7QI-BMn6Cp6lJWQgAKqVZIZsgNc-NFmL1c1Y6T_W0QbZifKEUlGR0nWyAkBpUwTbJ_d0zhg5t_9p4NzY2Q19lw7yr3j12aTeEfnBhbFzM-jprfJzaxmcYBwzjl-B56tD_HHbIWo1tdLtz3yaPF-cPZ1f5ze3l9dniJrdCsTFHYbFQlC0N1BVdMqMlR8qKGkBSZRhaUxsjagOgHC2WaCpVCUM5R6u0c3ybHH37pvfeJhfHsmuidW2L3vVTLDWwgmsQCTz4B770U_Dpt1JLTbkBbRJ08g3Z0McYXF0OoekwvJdAy8-sy0X5J-uk2J9tp2Xnql9-DjcBhzOA0WJbB_S2ib-cBGaYUPwDytKGFg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>757038178</pqid></control><display><type>article</type><title>Pharmacokinetic and pharmacodynamic properties of insulin aspart and human insulin</title><source>Springer Nature</source><creator>ØSTERBERG, Ole ; ERICHSEN, Lars ; INGWERSEN, Steen H ; PLUM, Anne ; POULSEN, Henrik E ; VICINI, Paolo</creator><creatorcontrib>ØSTERBERG, Ole ; ERICHSEN, Lars ; INGWERSEN, Steen H ; PLUM, Anne ; POULSEN, Henrik E ; VICINI, Paolo</creatorcontrib><description>The preferred approach to determine the pharmacokinetic (PK) and pharmacodynamic (PD) properties of insulin analogues is the euglycemic glucose clamp. Currently non-compartmental data analytical approaches are used to analyze data. The purpose of the present study is to propose a novel compartmental-model for analysis of data from glucose clamp studies. Data used in this trial only involved 18 of the 20 originally treated subjects. Data was obtained from a crossover trial where 18 healthy subjects each received a single subcutaneous (s.c.) dose of 1.2 nmol/kg (body weight) insulin aspart (IAsp) or 1.2 nmol/kg human insulin (HI) during a euglycemic glucose clamp after overnight fast. Serum insulin and glucose concentrations were measured and the glucose infusion rate (GIR) was adjusted after dosing, to maintain blood glucose near basal levels. Individual model parameters were estimated for IAsp, HI, and the corresponding glucose and GIR data. We found statistically significant differences between most of the HI and IAsp pharmacokinetic parameters, including the sigmoidicity of the time course of absorption (1.5 for HI vs. 2.1 for IAsp (unit less), P = 0.0005, Wilcoxon Signed-rank test), elimination rate constant (0.010 min-1 for HI vs. 0.016 min-1 for IAsp (P = 0.002)). The PD model parameters were mostly not different, except for the rate of insulin action (0.012 min-1 for HI vs. 0.017 min-1 for IAsp (P = 0.03)). The model may provide a framework to account for different PK properties when estimating the PD properties of insulin and insulin analogues in glucose clamp experiments.</description><identifier>ISSN: 1567-567X</identifier><identifier>EISSN: 1573-8744</identifier><identifier>DOI: 10.1023/a:1025594110558</identifier><identifier>PMID: 14571692</identifier><language>eng</language><publisher>Dordrecht: Springer</publisher><subject>Adult ; Biological and medical sciences ; Diabetes ; Hormones. Endocrine system ; Humans ; Insulin - analogs &amp; derivatives ; Insulin - blood ; Insulin - pharmacokinetics ; Insulin Aspart ; Medical sciences ; Models, Biological ; Pharmacology. Drug treatments ; Statistics, Nonparametric</subject><ispartof>Journal of pharmacokinetics and pharmacodynamics, 2003-06, Vol.30 (3), p.221-235</ispartof><rights>2004 INIST-CNRS</rights><rights>Plenum Publishing Corporation 2003</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c462t-a4ca9602b81fd0b28753a029f1150682ac8f884f8116e09ba8d6d48033ac67ee3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=15128246$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14571692$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>ØSTERBERG, Ole</creatorcontrib><creatorcontrib>ERICHSEN, Lars</creatorcontrib><creatorcontrib>INGWERSEN, Steen H</creatorcontrib><creatorcontrib>PLUM, Anne</creatorcontrib><creatorcontrib>POULSEN, Henrik E</creatorcontrib><creatorcontrib>VICINI, Paolo</creatorcontrib><title>Pharmacokinetic and pharmacodynamic properties of insulin aspart and human insulin</title><title>Journal of pharmacokinetics and pharmacodynamics</title><addtitle>J Pharmacokinet Pharmacodyn</addtitle><description>The preferred approach to determine the pharmacokinetic (PK) and pharmacodynamic (PD) properties of insulin analogues is the euglycemic glucose clamp. Currently non-compartmental data analytical approaches are used to analyze data. The purpose of the present study is to propose a novel compartmental-model for analysis of data from glucose clamp studies. Data used in this trial only involved 18 of the 20 originally treated subjects. Data was obtained from a crossover trial where 18 healthy subjects each received a single subcutaneous (s.c.) dose of 1.2 nmol/kg (body weight) insulin aspart (IAsp) or 1.2 nmol/kg human insulin (HI) during a euglycemic glucose clamp after overnight fast. Serum insulin and glucose concentrations were measured and the glucose infusion rate (GIR) was adjusted after dosing, to maintain blood glucose near basal levels. Individual model parameters were estimated for IAsp, HI, and the corresponding glucose and GIR data. We found statistically significant differences between most of the HI and IAsp pharmacokinetic parameters, including the sigmoidicity of the time course of absorption (1.5 for HI vs. 2.1 for IAsp (unit less), P = 0.0005, Wilcoxon Signed-rank test), elimination rate constant (0.010 min-1 for HI vs. 0.016 min-1 for IAsp (P = 0.002)). The PD model parameters were mostly not different, except for the rate of insulin action (0.012 min-1 for HI vs. 0.017 min-1 for IAsp (P = 0.03)). The model may provide a framework to account for different PK properties when estimating the PD properties of insulin and insulin analogues in glucose clamp experiments.</description><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Diabetes</subject><subject>Hormones. Endocrine system</subject><subject>Humans</subject><subject>Insulin - analogs &amp; derivatives</subject><subject>Insulin - blood</subject><subject>Insulin - pharmacokinetics</subject><subject>Insulin Aspart</subject><subject>Medical sciences</subject><subject>Models, Biological</subject><subject>Pharmacology. Drug treatments</subject><subject>Statistics, Nonparametric</subject><issn>1567-567X</issn><issn>1573-8744</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><recordid>eNpdkEtLxTAQhYMovtfupAi6q2byrruL-AJBEQV3ZW6aYrVNa9Iu_PdGrYguhhlmvnMYDiF7QI-BMn6Cp6lJWQgAKqVZIZsgNc-NFmL1c1Y6T_W0QbZifKEUlGR0nWyAkBpUwTbJ_d0zhg5t_9p4NzY2Q19lw7yr3j12aTeEfnBhbFzM-jprfJzaxmcYBwzjl-B56tD_HHbIWo1tdLtz3yaPF-cPZ1f5ze3l9dniJrdCsTFHYbFQlC0N1BVdMqMlR8qKGkBSZRhaUxsjagOgHC2WaCpVCUM5R6u0c3ybHH37pvfeJhfHsmuidW2L3vVTLDWwgmsQCTz4B770U_Dpt1JLTbkBbRJ08g3Z0McYXF0OoekwvJdAy8-sy0X5J-uk2J9tp2Xnql9-DjcBhzOA0WJbB_S2ib-cBGaYUPwDytKGFg</recordid><startdate>20030601</startdate><enddate>20030601</enddate><creator>ØSTERBERG, Ole</creator><creator>ERICHSEN, Lars</creator><creator>INGWERSEN, Steen H</creator><creator>PLUM, Anne</creator><creator>POULSEN, Henrik E</creator><creator>VICINI, Paolo</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20030601</creationdate><title>Pharmacokinetic and pharmacodynamic properties of insulin aspart and human insulin</title><author>ØSTERBERG, Ole ; ERICHSEN, Lars ; INGWERSEN, Steen H ; PLUM, Anne ; POULSEN, Henrik E ; VICINI, Paolo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c462t-a4ca9602b81fd0b28753a029f1150682ac8f884f8116e09ba8d6d48033ac67ee3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Diabetes</topic><topic>Hormones. Endocrine system</topic><topic>Humans</topic><topic>Insulin - analogs &amp; derivatives</topic><topic>Insulin - blood</topic><topic>Insulin - pharmacokinetics</topic><topic>Insulin Aspart</topic><topic>Medical sciences</topic><topic>Models, Biological</topic><topic>Pharmacology. Drug treatments</topic><topic>Statistics, Nonparametric</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>ØSTERBERG, Ole</creatorcontrib><creatorcontrib>ERICHSEN, Lars</creatorcontrib><creatorcontrib>INGWERSEN, Steen H</creatorcontrib><creatorcontrib>PLUM, Anne</creatorcontrib><creatorcontrib>POULSEN, Henrik E</creatorcontrib><creatorcontrib>VICINI, Paolo</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Virology and AIDS Abstracts</collection><collection>ProQuest - Health &amp; Medical Complete保健、医学与药学数据库</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of pharmacokinetics and pharmacodynamics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>ØSTERBERG, Ole</au><au>ERICHSEN, Lars</au><au>INGWERSEN, Steen H</au><au>PLUM, Anne</au><au>POULSEN, Henrik E</au><au>VICINI, Paolo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pharmacokinetic and pharmacodynamic properties of insulin aspart and human insulin</atitle><jtitle>Journal of pharmacokinetics and pharmacodynamics</jtitle><addtitle>J Pharmacokinet Pharmacodyn</addtitle><date>2003-06-01</date><risdate>2003</risdate><volume>30</volume><issue>3</issue><spage>221</spage><epage>235</epage><pages>221-235</pages><issn>1567-567X</issn><eissn>1573-8744</eissn><abstract>The preferred approach to determine the pharmacokinetic (PK) and pharmacodynamic (PD) properties of insulin analogues is the euglycemic glucose clamp. Currently non-compartmental data analytical approaches are used to analyze data. The purpose of the present study is to propose a novel compartmental-model for analysis of data from glucose clamp studies. Data used in this trial only involved 18 of the 20 originally treated subjects. Data was obtained from a crossover trial where 18 healthy subjects each received a single subcutaneous (s.c.) dose of 1.2 nmol/kg (body weight) insulin aspart (IAsp) or 1.2 nmol/kg human insulin (HI) during a euglycemic glucose clamp after overnight fast. Serum insulin and glucose concentrations were measured and the glucose infusion rate (GIR) was adjusted after dosing, to maintain blood glucose near basal levels. Individual model parameters were estimated for IAsp, HI, and the corresponding glucose and GIR data. We found statistically significant differences between most of the HI and IAsp pharmacokinetic parameters, including the sigmoidicity of the time course of absorption (1.5 for HI vs. 2.1 for IAsp (unit less), P = 0.0005, Wilcoxon Signed-rank test), elimination rate constant (0.010 min-1 for HI vs. 0.016 min-1 for IAsp (P = 0.002)). The PD model parameters were mostly not different, except for the rate of insulin action (0.012 min-1 for HI vs. 0.017 min-1 for IAsp (P = 0.03)). The model may provide a framework to account for different PK properties when estimating the PD properties of insulin and insulin analogues in glucose clamp experiments.</abstract><cop>Dordrecht</cop><pub>Springer</pub><pmid>14571692</pmid><doi>10.1023/a:1025594110558</doi><tpages>15</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1567-567X
ispartof Journal of pharmacokinetics and pharmacodynamics, 2003-06, Vol.30 (3), p.221-235
issn 1567-567X
1573-8744
language eng
recordid cdi_proquest_miscellaneous_71293714
source Springer Nature
subjects Adult
Biological and medical sciences
Diabetes
Hormones. Endocrine system
Humans
Insulin - analogs & derivatives
Insulin - blood
Insulin - pharmacokinetics
Insulin Aspart
Medical sciences
Models, Biological
Pharmacology. Drug treatments
Statistics, Nonparametric
title Pharmacokinetic and pharmacodynamic properties of insulin aspart and human insulin
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T03%3A25%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pharmacokinetic%20and%20pharmacodynamic%20properties%20of%20insulin%20aspart%20and%20human%20insulin&rft.jtitle=Journal%20of%20pharmacokinetics%20and%20pharmacodynamics&rft.au=%C3%98STERBERG,%20Ole&rft.date=2003-06-01&rft.volume=30&rft.issue=3&rft.spage=221&rft.epage=235&rft.pages=221-235&rft.issn=1567-567X&rft.eissn=1573-8744&rft_id=info:doi/10.1023/a:1025594110558&rft_dat=%3Cproquest_cross%3E71293714%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c462t-a4ca9602b81fd0b28753a029f1150682ac8f884f8116e09ba8d6d48033ac67ee3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=757038178&rft_id=info:pmid/14571692&rfr_iscdi=true